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ORIGINAL ARTICLE
Antiarrhythmic Effects of Combining Dofetilide and
Ranolazine in a Model of Acutely Induced Atrial Fibrillation
in Horses
Helena Carstensen, DVM,* Line Kjær, DVM,* Maria Mathilde Haugaard, PhD,* Mette Flethøj, PhD,*
Eva Zander Hesselkilde, DVM,* Jørgen K. Kanters, MD,† Steen Pehrson, PhD,‡ Rikke Buhl, PhD,*
and Thomas Jespersen, PhD†
Background: Antiarrhythmic compounds against atrial ﬁbrilla-
tion (AF) often have reduced efﬁcacy and may display cardiac
and/or noncardiac toxicity. Efﬁcacy can be improved by com-
bining 2 compounds with distinct mechanisms, and it may be
possible to use lower doses of each compound, thereby reducing
the likelihood of adverse side effects. The purpose of this study
was to investigate whether the effective doses of dofetilide and
ranolazine can be reduced if the drugs are combined.
Methods: Dofetilide, ranolazine, and a combination of these were
administered in 4 incremental dosing regimens to horses with acutely
pacing-induced AF. Time to cardioversion, atrial effective refractory
period, and AF vulnerability and duration were assessed.
Results: Of 8 horses, 6 cardioverted to sinus rhythm after
infusion with a combination of 0.889 mg/kg dofetilide and
0.104 mg/kg ranolazine. Two horses cardioverted with 0.104
mg/kg ranolazine alone, and 3 cardioverted with 0.889 mg/kg
dofetilide alone. The combination therapy decreased AF vulner-
ability (P , 0.05) and AF duration (P , 0.05). No change in
atrial effective refractory period was detected with any of the
drugs.
Conclusions: The combination of dofetilide and ranolazine
showed increased antiarrhythmic effects on acutely induced AF in
horses, affecting time to cardioversion, AF vulnerability, and AF
duration.
Key Words: atrial ﬁbrillation, horse, dofetilide, ranolazine, combi-
nation therapy
(J Cardiovasc Pharmacol 2018;71:26–35)
INTRODUCTION
Atrial ﬁbrillation (AF) is the most common clinical
arrhythmia in both humans and horses.1 However, current
treatment options for restoring sinus rhythm are not optimal
because available antiarrhythmic compounds possess cardio-
vascular and/or noncardiovascular toxicity, and the efﬁcacy is
limited.2 In recent years, ranolazine has been investigated for
its antiarrhythmic potential both alone and in combination.3–5
Ranolazine has previously been reported to suppress QT-
related arrhythmias,6 but a recent study reported an increased
risk of torsades de pointes ventricular tachycardia (TdP) asso-
ciated with its use.7 Ranolazine blocks a number of ion cur-
rents, most notably the late sodium current (INa,late) and in
higher doses, the peak sodium current (INa,peak) and the rapid
activating delayed rectiﬁer potassium current (IKr) also.8,9
Dofetilide is a potent IKr blocker and is used as an
antiarrhythmic agent in the treatment of AF.2 In the DIA-
MOND study,10 dofetilide was found to be effective for both
cardioversion and maintenance of sinus rhythm in patients
with congestive heart failure and AF. However, use of dofe-
tilide may result in TdP because of a prolongation of the QT
interval.11 This QT-prolonging effect is dose-dependent,2 and
by combining the compound with another antiarrhythmic
compound, it may be possible to reduce the dose of individual
compounds, thus minimizing their adverse effects. Further-
more, the combination of more than one drug is hypothesized
to increase the efﬁcacy against AF, and some studies have
already addressed this using ranolazine.4,12,13
The horse has been advocated as a promising animal
model of AF because of the similarity to human physiology,
including the cardiac ion channel distribution14 and occur-
rence of AF.1 Furthermore, AF can be easily induced exper-
imentally in horses. Our research group has developed
a model of acutely induced AF in horses, which allows us
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to examine the antiarrhythmic effects of different
compounds.14,15
The present study was designed to test the hypothesis
that combining dofetilide with ranolazine will make it
possible to reduce the doses of both drugs to subefﬁcacious
levels and still reach the same antiarrhythmic potential as
when either compound is used alone in higher doses.
METHODS
The study was approved by the local ethical committee
at the Department of Veterinary Clinical Sciences, University
of Copenhagen and The Danish Animal Experiments Inspec-
torate (license number 2012-15-2934-00198) and was per-
formed in accordance with the European Commission
Directive 86/609/EEC.
Twelve Standardbred horses were included [body weight
(BW) 502 6 37 kg, age 8.3 6 3.5 years], of which 3 mares
were enrolled in a safety study, and 6 mares and 3 geldings in an
electrophysiology study (seeMaterial Table S1, Supplemental
Digital Content 1, http://links.lww.com/JCVP/A283). Before
the study, the horses underwent a clinical examination and
had a 24-hour electrocardiography (ECG) recording (Tele-
vet, Engel Engineering Services GmbH, Heusenstamm,
Germany), as well as a routine echocardiographic examina-
tion (2-D, M-mode and colour-ﬂow Doppler; Vivid I ultra-
sound machine with a 1.5 mHz phased array probe, GE
Healthcare, Horten, Norway). Only horses with no signs of
cardiovascular disease were included. All horses were
included in 4 procedures [saline (control), dofetilide, rano-
lazine, and the combination of dofetilide and ranolazine],
with 7 days recovery period in between. All procedures were
performed on nonsedated horses restrained in a stock with
access to hay and water. The horses were trained to stand
quietly for longer periods before the studies, and therefore,
no anesthesia was needed.
Drugs
Dofetilide (Cat. No. 3757, Tocris Bioscience, R&D
systems, Abingdon, United Kingdom) was dissolved in
50% Poly (ethylene glycol) average Mn 400 (202398 Aldrich,
Sigma-Aldrich, MO) and 50% saline (NaCl 9 mg/mL, B.
Braun, Melsungen, Germany) to a solution of 0.04 mg/mL.
Ranolazine dihydrochloride (Cat. No. 3118, Tocris Biosci-
ence, R&D systems, Abingdon, United Kingdom) was dis-
solved in saline to a solution of 14 mg/mL. The ranolazine
solution was pH-calibrated using 1M NaOH to a pH of just
above 5.
Safety Study
The safety study is described in detail in the
Supplemental Digital Content 1 (see Table S1,
http://links.lww.com/JCVP/A283).
FIGURE 1. Experimental protocol. A, Outline of the experimental protocol. B, Schematic overview of the doses used at the
different drug infusions.
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Electrophysiology
An overview of the experimental protocol is presented in
Figure 1A. Two multipolar steerable nonﬁxative electrodes
(Inquiry Steerable Diagnostic Catheter, 6Fr/110 cm; St. Jude
Medical, MN) were used for each horse; 1 for atrial pacing
and 1 for obtaining atrial electrograms, as previously
described.15 The electrodes were placed through 2 introducer
sheaths (One Piece/Tuohy-Borst Catheter Introducer with Inte-
gral Hemostasis Valve, 8F, Argon Medical Devices, Holte,
Denmark) in 1 of the jugular veins and advanced to the right
atrium using the deﬂections on the electrogram to determine
positioning. The recording electrode was placed so that the
deﬂection on the atrial electrogram appeared in conjunction with
the P wave on 2 simultaneously recorded surface ECGs. The
pacing electrode was positioned to have consistent atrial capture
at 60 beats per minute (bpm), with a threshold of excitation
lower than 1.4 mA. Intra-atrial recordings and surface ECGs
were monitored and stored for later analysis using Labchart 7
software (ADInstruments, Oxford, United Kingdom).
One horse (ID11) was excluded from the study, as it did
not complete the combination procedure because of the
development of supraventricular tachycardia during an AF
episode before drug administration.
Atrial Refractory Period
Atrial effective refractory periods (aERPs) were deter-
mined to be the longest S1-S2 stimuli interval failing to
capture with 9 basic stimuli (S1) followed by an extra
stimulus (S2) with 10-millisecond increments (pulse width
2 milliseconds, current 3 mA). Measurements were performed
3 times and averaged at atrial pacing rates of 60, 75, 120, and
182 bpm before and after drug administration. Each S1-S2
interval was applied a minimum of 3 times at each pacing
rate, and aERP was determined as the S1-S2 interval before
the one at which complete or intermittent atrial capture
occurred.
AF Induction, AF Vulnerability, and AF Duration
AF was induced after aERP measurements using
a current of 10 mA and burst-pacing at 50 Hz for 4–6 sec-
onds. Drug treatment was initiated once the horse developed
an AF episode longer than 15 minutes. After drug adminis-
tration and cardioversion, aERP was measured and an attempt
was made to reintroduce AF. After treatment, burst-pacing
was performed until AF lasted for more than 15 minutes, or
a maximum of 15, 30, or 45 times in cases where the induc-
tion of AF before drug administration required #15, #30,
and #45 burst-pacings, respectively. The number of burst-
pacings required until AF that lasted for more than 15 minutes
was counted to evaluate AF vulnerability. The mean duration
of AF episodes after burst-pacings (maximum 15 minutes)
was termed AF duration.
Drug Treatment
The order of saline, dofetilide, and ranolazine proce-
dures was randomized, whereas all horses received the
FIGURE 2. QRS duration during drug treatment. QRS duration during the 4 safety procedures: saline/control (A), dofetilide (B),
ranolazine (C), and a combination of dofetilide and ranolazine (D). The gray areas represent dose administrations. *P , 0.05;
**P , 0.01.
Carstensen et al J Cardiovasc Pharmacol  Volume 71, Number 1, January 2018
28 | www.jcvp.org Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc.
combination treatment in their last procedure. Dofetilide
was administered intravenously at a dose of 8.0 mg/kg BW,
in accordance with recommendations in humans.16 Rano-
lazine was administered intravenously at a dose of 2.4 mg/
kg BW, in accordance with studies in pigs,17 as these stud-
ies have demonstrated antiarrhythmic effects using an
intravenous route of administration, whereas studies in hu-
mans use oral administration. Saline was administered at
0.2 mL/kg BW to mimic the volume of the drugs infused.
All solutions were administered at a rate of 0.0125 mL/kg
BW/min according to the recommendations for dofetilide
administration.16,18 The doses were administered in 4 steps
—each with a 3-fold increase in the total dose (Fig. 1B).
Each administration step was given with 20-minute inter-
vals. For the combination procedure, ranolazine was
administered in 4 steps, using the same dose as when
administered alone. Dofetilide was given with the ﬁrst dose
of ranolazine at a dose of 0.889 mg/kg, as this corresponded
to the last noncardioverting dose of dofetilide when used
alone. All horses were given all 4 doses of each drug
regardless of cardioversion time, to allow for the compar-
ison of electrophysiology parameters.
ECG Analysis
ECGs were obtained throughout each procedure and
for 24 hours after drug infusion using a Holter unit
(Televet).15 QT intervals and QRS durations were manu-
ally analyzed on lead II. Most measurements were made at
ventricular rates of 30–50 bpm (resting heart rate for horses
is 28–40 bpm); however, the rates have been up to a max-
imum of 105 bpm. The QT measurements were corrected
using a piecewise linear regression model speciﬁcally
developed for horses. This regression model shows the
lowest prediction errors at almost all heart rates when com-
pared with other models.19 Because of technical problems,
ECGs were not available for analysis for 2 dofetilide and 2
ranolazine procedures.
Data Analysis
All data are presented as mean 6 standard error of
measurement. Analyses were performed using GraphPad
Prism 5 software (GraphPad Software, San Diego, CA) or
R 3.3.1 software (The R Foundation for Statistical Comput-
ing, Vienna, Austria), with P # 0.05 considered signiﬁcant.
Changes in QRS duration and corrected QT intervals (QTc) in
the animals of the safety study were analyzed by 1-way
repeated analysis of variance followed by a Dunnett’s multi-
ple comparisons test using a time point of 5 minutes before
drug injection, T(-5), as a reference. The QRS duration and
QTc from the electrophysiology study were analyzed using
a linear mixed model, and aERP data were analyzed by 2-way
repeated-measures analysis of variance, followed by the
Bonferroni post-test for pairwise comparisons. Changes in
excitation threshold were analyzed using Wilcoxon signed-
rank tests. AF vulnerability and AF duration were analyzed
by Mann–Whitney U tests. Time to cardioversion was
FIGURE 3. Corrected QT intervals (QTc) during drug treatment. QTc during the 4 safety procedures: saline/control (A), dofetilide
(B), ranolazine (C), and a combination of dofetilide and ranolazine (D). The gray areas represent dose administrations. *P , 0.05;
**P , 0.01; ***P , 0.001.
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analyzed by 1-way repeated analysis of variance, followed by
Dunnett’s multiple comparisons test.
RESULTS
Safety of Dofetilide and Ranolazine
The safety of dofetilide (8.0 mg/kg BW) and ranolazine
(2.4 mg/kg BW) for use in horses was ﬁrst assessed by
administering the compounds in 2 steps to healthy horses
without AF, and monitoring them closely.
None of the horses in the study experienced adverse
clinical reactions or an elevation of the cardiac biomarkers
cardiac Troponin I and Creatinine Kinase fraction MB as
a result of the drugs either alone or in combination
(see Material Figure 1, Supplemental Digital Content 1,
http://links.lww.com/JCVP/A283), and blood pressure re-
mained unchanged after drug administration in the safety
study (see Material Figure 1, Supplemental Digital Con-
tent 1, http://links.lww.com/JCVP/A283). The QRS duration
and QTc in the safety study were prolonged by all treatments
(Figs. 2 and 3). The T-wave morphology changed after dofeti-
lide administration both alone and in combination in all 3 safety
procedures (Figs. 4B, D). When the T wave was initially posi-
tive, it changed to a biphasic or negative deﬂection, and when it
was initially biphasic, it became negative. This phenomenon
occurred despite a steady heart rate, and was not observed after
administration of saline or ranolazine alone (Figs. 4A, C).
Electrophysiology
The time to spontaneous cardioversion after the ﬁrst drug
injection was compared with the time to spontaneous cardio-
version after saline injection in the time-matched control
procedures (Fig. 5). The mean time to cardioversion in minutes
was 128.3 6 29.9, 67.0 6 22.7, 50.8 6 10.2, and 24.5 6 12.6
in the control, dofetilide, ranolazine, and combination procedure
groups, respectively (see Material Table S2, Supplemental
Digital Content 1, http://links.lww.com/JCVP/A283). Both ra-
nolazine (P , 0.05) and the combination treatment (P , 0.05)
signiﬁcantly shortened the time to cardioversion. The combina-
tion of 0.889 mg/kg dofetilide and 0.104 mg/kg ranolazine car-
dioverted 6 of 8 horses (dose 1 combination, Fig. 5), whereas the
same doses of the drugs administered individually were only
able to cardiovert 3 (dose 2 dofetilide, Fig. 5) and 2 horses (dose
1 ranolazine, Fig. 5), respectively. Infusion of 8.0 mg/kg dofe-
tilide did not result in cardioversion rates that were different
from those in the control group.
The threshold of excitation, aERP, AF vulnerability,
and AF duration were studied before treatment and after the
FIGURE 4. Changes in T-wave morphology following drug treatment. ECGs (lead II) from the same horse before and after
administration of drugs: saline (A), dofetilide (B), ranolazine (C), and a combination of dofetilide and ranolazine (D). Note the
changes in the T-wave morphology after dofetilide and combination treatment (B, D).
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horses had received the full dose of each drug. It was not
possible to perform the investigations after drug infusion in 6
saline, 1 dofetilide, and 1 combination procedure, because the
horses were not in sinus rhythm. The threshold of excitation
was in the range of 0.3–1.3 mA before drug treatment, and
after drug treatment 0.3–1.1 mA (P . 0.05 for all
procedures). In the control animals, aERP varied with pacing
frequency from ;240 milliseconds at 60 bpm to ;180 milli-
seconds at 182 bpm (Fig. 6A). None of the treatments signif-
icantly prolonged aERP (Fig. 6). The combination treatment
decreased AF vulnerability (P , 0.05) and AF duration (P ,
0.05), whereas the drugs used individually had no effect on
these parameters (Figs. 7 and 8).
With respect to ventricular electrophysiology, none of
the treatments altered the QRS duration when compared with
the control group, yet this was signiﬁcantly prolonged in the
ranolazine group when compared with the combination group
(DQRSran = 0.00049 6 0.001 seconds, DQRScombi =
20.0020 6 0.001 seconds, P , 0.05; Fig. 9B). Dofetilide,
ranolazine, and the combination treatment all signiﬁcantly
increased QTc when compared with the control group
(DQTcdof = 0.021 6 0.002 seconds, DQTcran = 0.013 6
0.002 seconds, DQTccombi = 0.018 6 0.002 seconds, P ,
0.001 for all 3 comparisons; Fig. 9C). No signiﬁcant differ-
ences were found when comparing either drug used individ-
ually to the combination, but dofetilide prolonged the QTc
more than ranolazine (P , 0.001). The maximum QTc
reached was 0.43 6 0.01 seconds in the control procedure,
0.48 6 0.01 seconds after dofetilide treatment, 0.44 6 0.01
seconds after ranolazine treatment, and 0.45 6 0.01 seconds
after combination treatment. No ventricular arrhythmias were
detected during or after any of the drug treatments.
FIGURE 5. Time from start of drug administration to car-
dioversion. The percentage of horses remaining in AF as
a function of time (in minutes). Time 0 is the start of the first
drug administration. The gray areas represent the 4 dose ad-
ministrations. In all groups n = 8.
FIGURE 6. Right aERP after drug treatment. The aERP was measured at different pacing rates before and after the infusion of
drugs: saline (A), dofetilide (B), ranolazine (C), and the combination of dofetilide and ranolazine (D). A, Only 2 horses car-
dioverted within the time of the experiment, therefore, n = 8 at the baseline and n = 2 in the saline group. B, One horse did not
cardiovert within the time of the experiment and 1 horse had unstable placement of the electrode: n = 6. C, n = 8. D, One horse
did not cardiovert within the time of the experiment: n = 7.
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DISCUSSION
This study is the ﬁrst to examine the effects of
combining dofetilide and ranolazine for the termination of
AF. The combination protocol demonstrated antiarrhyth-
mic potential by cardioverting horses in acutely induced
AF and decreasing AF vulnerability and duration after drug
administration.
Combination Therapy in the Treatment of AF
One case report has previously found the combination of
dofetilide and ranolazine to be effective in maintaining sinus
rhythm in a patient with a history of paroxysmal AF.20 Several
studies have combined ranolazine with amiodarone or dronedar-
one, ﬁnding the combination to be superior to either drug used
individually.4,12,13,21,22 Dofetilide has also been proposed for use
in combination therapy for the termination of AF.23 Previous
studies combining antiarrhythmic compounds in the treatment of
AF have shown synergistic effects.12,13,23,24 In this study, we
demonstrated an increased antiarrhytmic effect for the combina-
tion of dofetilide and ranolazine relative to monotherapy with
either drug. We demonstrated that the combination of 0.889
mg/kg dofetilide and 0.104 mg/kg ranolazine cardioverted 6 of
8 horses, whereas the individual use of these drugs at the same
doses were only able to cardiovert 3 and 2 of the 8 horses,
respectively. Furthermore, a decrease in AF vulnerability and
duration only occurred after treatment with the combination of
drugs. This protective mechanism against reinduction of AF
corresponds well with previous ﬁndings of a combination strat-
egy that was able to decrease the AF burden in patients with
paroxysmal AF.4,20
Ranolazine as Monotherapy in AF
Ranolazine has shown the ability to terminate AF and
atrial ﬂutter in a canine sterile pericarditis model,25 and the
drug was able to cardiovert induced AF to atrial ﬂutter in
anesthetised pigs.17 In humans, a “pill-in-pocket”
approach, using a single oral dose of ranolazine to cardio-
vert AF of acute onset (between 3 and 48 hours of AF) was
successful in 72% of cases.5 However, it is worth noting
that no control group was included in this study, and spon-
taneous cardioversion is highly likely to have occurred in
some of the patients.5 Other studies have found ranolazine
useful for maintenance of sinus rhythm,26,27 whereas the
AF burden was not decreased in the HARMONY trial after
ranolazine administration alone.4 In this study, 2.4 mg/kg
of ranolazine produced a signiﬁcant antiarrhythmic effect,
which is in contrast to the individual use of dofetilide up to
a dose of 8.0 mg/kg. However, no effects on AF vulnera-
bility or AF duration were found with the administration of
either drug alone, indicating the lack of a protective effect
on the initiation of new AF episodes.
Atrial Electrophysiology and Underlying
Mechanisms
Both dofetilide and ranolazine have been reported to
cause an increase in aERP.3,17,18,21 In this study, ranolazine
resulted in aERP values similar to the baseline, and the 10–
15-millisecond prolongation observed in aERP after dofe-
tilide (Fig. 6B) did not reach statistical signiﬁcance. As
dofetilide alone did not display signiﬁcant antiarrhythmic
properties, it may be the case that the IKr antiarrhythmic
FIGURE 7. Induction of AF. Electro-
gram (EGM) from the right atrium,
ECG, and pacing from the same horse
before (A) and after (B) administration
of the combination therapy with do-
fetilide and ranolazine. In both images
tachypacing is performed leaving no
visible gap between each stimuli. Note
the short AF episodes (AF duration)
after AF induction after combination
therapy (B).
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target is not expressed in a sufﬁcient level in horse atria to
lead to cardioversion. The chosen maximum dose was
based on the recommendations for safe and efﬁcacious
dosing in humans,16 which can be argued not to apply in
horses. The expression of the gene encoding for the IKr
(KCNH2) in the equine atria has been shown,14,28 but
a higher expression of KCNH2 was found in the right ven-
tricle compared with the right atrial appendage,14 in con-
trast to the uniform expression level in human atrial and
ventricular myocardium.29 The functional role of IKr has
only been demonstrated in equine ventricular tissue,30 and
therefore, further studies are warranted. Despite an
increased antiarrhythmic effect seen with the combination
of drugs no changes in aERP were seen. It is unlikely that
dofetilide acted in another way than IKr block and changes
in repolarization. The possible explanations for the lack of
effect on aERP are therefore; 1) dofetilide acted by block-
ing IKr and prolonging the action potential duration, but the
prolongations were not sufﬁciently large to achieve statis-
tical signiﬁcance; 2) dofetilide acted through IKr block, but
the effect was mediated by changes in action potential
morphology that enhanced ranolazine-induced INa block
but did not signiﬁcantly prolong the action potential dura-
tion.31 In a study by Aguilar et al,31 it was shown that
potassium channel block potentiates the AF-selective
antiarrhythmic effects of optimized sodium-channel
blockade. The mechanisms behind this synergism are rate
dependent, and the effect is therefore largest in the atria
during AF.
Effect of Drugs on Ventricular
Electrophysiology
It has been shown that dofetilide can cause TdP in
humans.2 No adverse cardiovascular or noncardiovascular
reactions were encountered in the horses receiving ranola-
zine or dofetilide in this study. Both drugs displayed QTc-
prolonging effects, in accordance with studies in other
species.6,9,23 Dofetilide prolonged the QTc more than ra-
nolazine, presumably because dofetilide mainly blocks IKr,
and this prolongs the entire repolarisation phase of the
action potential. Conversely, ranolazine blocks INa,late with
great potency in ventricular myocytes, thereby shortening
the early repolarization.8,32 None of the compounds pro-
longed the QRS interval, indicating that the ventricular
effects were on the repolarization of the action potential.
Human studies have shown similar QRS results after dofe-
tilide administration, but a slight prolongation of the QRS
duration after ranolazine administration.32 It is worth not-
ing that in the safety part of this study, some prolongation
of the QRS interval was seen, but these results were based
on only 3 horses (Fig. 2). Little is known about the T-wave
morphology in horses, but it was evident that dofetilide
changed the morphology in this study (Figs. 4B, D). Infu-
sion of ranolazine also seems to change the morphology, as
the T wave appears to have smaller amplitude (Fig. 4C). An
IKr block induced by dofetilide or ranolazine is known to
affect T-wave morphology in humans by causing
concentration-dependent T-wave ﬂatness, asymmetry, and
notching.33 The changes in T-wave morphology observed
FIGURE 8. Atrial fibrillation (AF) vulnerability and mean AF duration after drug treatment. A, AF vulnerability presented as the
mean number of burst-pacings required to induce an AF episode of $15 minutes. B, AF duration is presented in box plots and
whiskers represent minimum to maximum values. In the dofetilide procedures n = 6, in the ranolazine procedures n = 7 and in the
combination procedures n = 7. * P , 0.05; ns = nonsignificant.
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in this study may be unique to horses and should be studied
further to determine causes and consequences.
A recent epidemiological study found an increased risk
of TdP related to the use of ranolazine in a population of
patients with prolonged QTc.7 By contrast, previous studies
have reported that ranolazine reduces ventricular arrhythmias
by suppressing early afterdepolarizations, despite the QTc-
prolonging effect.6,9 In a canine model, TdP was induced
using dofetilide, but when ranolazine was added, the number
of TdP episodes was signiﬁcantly decreased.6 No ventricular
arrhythmogenic events were noted in this study, despite the
observed QTc prolongation.
Study Limitations
The size of the study population poses an important
limitation, which became apparent when 2 horses cardio-
verted very early in the control procedures. The decision to
use 15 minutes of AF as the threshold for the start of
treatment was based on previous studies,15,34 yet it could be
argued that this was too short a time in this study.
Knowledge of the pharmacodynamics of dofetilide and
ranolazine in horses is currently lacking. More information on
this would be valuable to compare the ﬁndings from this
study to those in other species. In humans, the elimination
half-life of dofetilide is around 10 hours,35 and for ranolazine,
is around 1.5 hours.36 As a consequence, the dosing regimen
of this study (with 20 minutes in between treatments) is not
considered to be problematic in terms of comparisons
between dofetilide used alone and in combination. However,
ranolazine plasma concentrations may not have reached the
levels that could be expected if the total dose was given at
once.
The level of electrophysiological analysis is too limited
to deﬁne the exact mechanisms of interaction between
dofetilide and ranolazine. The mechanisms suggested in the
study therefore remain speculative. Furthermore, the mecha-
nism of AF in this model is unknown and extrapolation of
results should be performed with caution.
CONCLUSIONS
The combination of dofetilide and ranolazine showed
clear antiarrhythmic effects—terminating acutely induced
AF in horses, protecting from the reinduction of AF and
shortening AF episodes induced after treatment. Ranola-
zine as a monotherapy was also found to terminate AF,
but it did not display other antiarrhythmic effects. The
use of the drugs individually and in combination prolonged
the QTc, which may indicate the possibility of proarrhyth-
mic events in the ventricles, although no such events were
encountered.
FIGURE 9. Ventricular effects of drug treatments. A, ECG from the same horse before (1) and after (2) dofetilide administration
with illustration of QRS duration and QT interval. Heart rate is 36 bpm in both ECGs. B, QRS duration and (C) corrected QT
intervals (QTc) after drug treatment presented as the mean prolongation 6 SEM compared with the control group receiving
saline. #Represents significance levels of the comparison between the different drug treatments and the control group. *P, 0.05;
***P , 0.001; ###P , 0.001.
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